The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.
MSF authors describe medical activities for people for snakebite, including the importance of offering antivenom free of charge, though costly for MSF.
MSF, Unitaid and WHO authors discuss the need to improve access to liposomal amphotericin B (L-AmB) for the treatment of HIV-associated cryptococcal meningitis.